Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.
Novartis will pay $168 per Alcon share for the remaining 23% of the company, which are more favourable terms than...